CD274 and neoplasm: NSCLC is a highly dynamic condition and a combination of treatment approaches, including chemotherapy, along with a biomarker‐ (e.g. PD‐L1 expression) or molecular‐guided first‐ or second‐line therapy followed by prospective testing of the tumour or ccfDNA to monitor acquisition of resistance mutations may be of benefit.